amesit.wordpress.com
The Lexington-based biotech firm's third round include d the following investors: , a Boston investment firm; SR One Ltd., the venturs capital arm of British drug giant GlaxoSmithKline PLC; Newton venture capital firm Mediphase Ventur e Partners; and Westfield Capital Management, a Boston investment Concert noted that all investors from previous rounds -- Thred Arch Partners, TVM Capital, Skyline Ventures, Brookside Fund LP, Flagshilp Ventures, Greylock Partners, New Leaf Venturd Partners and QVT Fund LP -- also contributedx to the latest financing. The 40-person firm has now closer a totalof $95.
5 million througjh its three rounds of venture capital, according to its Its technology involves the use of a naturao element, deuterium, to modify validated drug compoundas to create so-called new chemical entities, or NCEs. The biotecbh firm said it plans to enter its firstf clinical trial in the second half of 2008 with an NCE treatmeng forhot flashes.
No comments:
Post a Comment